AJ Smith

Spreading health knowledge @wearehims & @wearehers. Mom of two kids. Formerly @SoFi & @smartasset. Previous life as a TV journalist. Views my own.

[AJ Smith @_AJ_Smith]

Enjoyed talking about how spending changes during #retirement with @YahooFinance. How do you think your budget will shift? https://t.co/kdlFMonRRs @smartasset #personalfinance #money #fintech

[andrewdudum @AndrewDudum]

Obesity is a condition people live with around the world. Millions of Canadians are affected, but access to effective treatment has been limited for too long, mostly because of price. With the first-ever generic semaglutide hitting the market, that changes.

Which is why we’re bringing Hims & Hers weight loss care to Canada in 2026.

We’ve built a model that is trusted by millions across the U.S. by making high-quality, personalized care more accessible and affordable, consistently leading in the categories that matter most to people.

Now we’re bringing that same approach to Canada: personalized treatments, 24/7 access to licensed providers, and care plans built around the individual — all at a fraction of today’s branded prices.

This is a major step forward for access. As the cost of critical medications comes down, we’re continuing to raise the standard of care, ensuring more people can get the treatments they need.

More on today’s news here: https://t.co/H35GRNdGIw

[hers @wearehers]

Introducing 𝗧𝗵𝗲 𝗛𝗲𝗿𝘀 𝗣𝗼𝗱𝗰��𝘀𝘁 with Dr. Jessica Shepherd. 🎧💙 Join Dr. Shepherd—a board-certified physician and Chief Medical Officer at Hers—for monthly conversations with medical experts and industry leaders on everything from weight loss and PCOS to menopause and mental health.

Tap the link to subscribe—the first episode drops on Thursday: https://t.co/ttVLSrFEY6

#womenshealth #fertilityexpert #telehealth #industryinsights #thoughtleadership

[andrewdudum @AndrewDudum]

We just shared our Q1 results. And our 2030 target: $6.5B in revenue, $1.3B in adjusted EBITDA. We're entering a new era of growth: deeper personalization, broader impact, and faster execution. The foundation is set. The roadmap is clear. We're just getting started.

[andrewdudum @AndrewDudum]

At the core of $hims is a simple yet powerful idea: we use precision medicine to personalize the delivery of existing, clinically studied medications. We are not bypassing the regulatory process or creating new drugs. We focus on delivering better care through personalization. Period.

Precision medicine is about using the right tools for the right patient at the right time – and it gets better with strategic innovation. Our holistic approach means increasingly integrating lab work, provider engagement, patient choice, and clinical data ensure that personalization is thoughtful, safe, evidence-based, and patient-centric.

We believe this approach will ultimately drive better clinical outcomes. We’re committed to integrity and transparency. We won’t claim improved efficacy until the data substantiates it. And we show our quality and safety process. We take a logical approach that lets patients and providers draw their own conclusions because we know that patients, not pharmaceutical profits, should drive our health care system.

Obviously, critical to personalization is the need to compound medication. Under our current health system, we do this in two very specific circumstances:

1. Drug shortages: We ensure patients have continued
access at affordable prices. While Big Pharma charges in the thousands, we fill the gap by giving people access at prices that can be in the hundreds.

2. Clinical necessity: We enable personalized treatment when commercially available options don’t meet individual patient needs, whether in dosages, administration, or the need for additional ingredients.

We do this because it is the right thing to do for the patient. We don’t compound every medication, even if we believe it would help our profits. For example, we never chose to compound tirzepatide, even though it could have been profitable. Why not? In part, its wide range of commercially available dosages support a lower side effect profile that reduces the likelihood an individual will require alteration to meet their needs.

We do compound semaglutide. Now that the FDA has determined the drug shortage for semaglutide has been resolved, we will continue to offer access to personalized treatments as allowed by law to meet patient needs. We’re also closely monitoring potential future shortages, as Novo Nordisk stated two weeks ago that it would continue to have “capacity limitations” and “expected continued periodic supply constraints and related drug shortage notifications.” We know that demand remains high, despite the $1200+ Novo Nordisk charges in the US compared to the $135-$300 it charges in its native Denmark.

Since we have spoken out on the need to fix today’s “Stuck & Sick” health care system, we’ve seen Big Pharma react by questioning the need for affordable compounded options or purposely scaring regular Americans by making broad strokes about the “safety” of compounded medicines.

Our commitment is clear: patient safety and regulatory integrity, and using precision, personalization, and necessity—not convenience—to align with the highest standards of care. Our goal: empower patients, empower providers, provide comprehensive choices tailored to the individual, and do it the right way.

Precision medicine is about making existing treatments work better for individuals. We’re proud to stand for thoughtful innovation, not shortcuts. Holistic care means incorporating more than medicine into lifestyle changes that lead to better outcomes. At the end of the day, better care is comprehensive – and personal.

[hims @wearehims]

The system wasn’t built to help us. It was designed to keep Americans sick & stuck. Let’s fight for a healthier America.

At Hims & Hers, we’re fighting back with care designed for you that’s accessible, affordable, & trustworthy. Because you deserve to feel great in your body: https://t.co/vd3kwDm4Yc

[hers @wearehers]

Big Pharma isn’t fighting for you. Here’s the ad they don’t want you to see: https://t.co/zrJBcantGn

[AJ Smith @_AJ_Smith]

Season 3 of @SoFi's podcast, The Important Part: Investing with @LizYoungStrat is now live with our first episode! We’re kicking things off with a series on retail investing, including trends, resources, and how to manage your portfolio: https://t.co/m9a4pGtfNc

[AJ Smith @_AJ_Smith]

2023 IRS Tax Refund Dates and Deadlines | SoFi https://t.co/MrktRRGUBv

[Liz Thomas @LizThomasStrat]

New survey data: @SoFi asked 1,000 investors to look back on '22 and ahead to '23. Tidbits: 37% said volatility caused them to make impulsive decisions, only 25% have no regrets about last year, and 85% plan to make changes this year. Read the rest here👇🏼https://t.co/lWuHhkW4z0

[Liz Thomas @LizThomasStrat]

💥New blog post: "How Would You Like That Cooked?" on the Fed's September statement and the market's double-take. https://t.co/xIzthDzQWM

[AJ Smith @_AJ_Smith]

https://t.co/MyzJ5zuTL5

[AJ Smith @_AJ_Smith]

Liz Looks at: The Fed’s June Statement https://t.co/8f6xjmGB8H

[SoFi @SoFi]

The Federal Reserve announced a raise in interest rates by 0.5%, which was widely anticipated by most. Here's our take on today’s news ➡️ https://t.co/7PkuLjeXab

[SoFi @SoFi]

The Federal Reserve announced a 0.25% increase in interest rates. But what does today's news mean for you? Learn more ➡️: https://t.co/B1HkS3g5mY

[AJ Smith @_AJ_Smith]

Happening right now!

[Barrett Scruggs @cbscruggs]

Tomorrow join me, @bcope51 and @JourneyToLaunch for the @SoFi Twitter spaces event discussing the current state of Black finances. Can’t wait to be part of an amazing panel and conversation.

https://t.co/2EX1JNEjnk

[SoFi @SoFi]

Considering becoming a #FirstTimeHomeBuyer during #inflation? This breaks down the factors at hand: https://t.co/djJivna7QG

[SoFi @SoFi]

Special holiday edition of the #invest column this week from our Head of Investment Strategy @LizYoungStrat breaking down the last Federal Reserve statement of the year: https://t.co/Q6gI8gRCKC

[AJ Smith @_AJ_Smith]

Fed Doubles Taper, Signals Three 2022 Hikes in Inflation Pivot https://t.co/kW8GKrxFss via @markets

[Liz Thomas @LizThomasStrat]

ISM Mfg came in at 61.1 for Nov, above 60.8 in Oct. Prices Paid came in at 82.4, below the estimate of 85.5 and below Oct's 85.7.

Could be the beginning of a move down in prices, but one data point does not make a trend. No chicken counting. Hawks are watching.

[CNBC @CNBC]

LISTEN NOW: It was a big day for earnings – Alphabet, Microsoft, Twitter, Visa and Robinhood shares all on the move. Listen and follow the @CNBCFastMoney podcast here or on your favorite podcast platform: https://t.co/aNPHC6269T